This webpage contains legacy information. The product is either no longer available from the supplier or has been delisted at Labome.
product summary
company name :
Invitrogen
other brands :
NeoMarkers, Lab Vision, Endogen, Pierce, BioSource International, Zymed Laboratories, Caltag, Molecular Probes, Research Genetics, Life Technologies, Applied Biosystems, GIBCO BRL, ABgene, Dynal, Affinity BioReagents, Nunc, Invitrogen, NatuTec, Oxoid, Richard-Allan Scientific, Arcturus, Perseptive Biosystems, Proxeon, eBioscience
product type :
antibody
product name :
Androgen Receptor Monoclonal Antibody (AR 441), Biotin
catalog :
MA5-13423
quantity :
500µL
price :
US 409
clonality :
monoclonal
host :
mouse
conjugate :
biotin
clone name :
AR 441
reactivity :
human
application :
western blot, immunohistochemistry, immunocytochemistry, immunoprecipitation, immunohistochemistry - paraffin section
citations: 55
Reference
Elebro K, Butt S, Dorkhan M, Jernstrom H, Borgquist S. Age at first childbirth and oral contraceptive use are associated with risk of androgen receptor-negative breast cancer: the Malmö Diet and Cancer Cohort. Cancer Causes Control. 2014;25:945-57 pubmed publisher
Agaimy A, Lell M, Schaller T, Märkl B, Hornung J. 'Neuroendocrine' middle ear adenomas: consistent expression of the transcription factor ISL1 further supports their neuroendocrine derivation. Histopathology. 2015;66:182-91 pubmed publisher
Rocha J, Zouanat F, Zoubeidi A, Hamel L, Benidir T, Scarlata E, et al. The Fer tyrosine kinase acts as a downstream interleukin-6 effector of androgen receptor activation in prostate cancer. Mol Cell Endocrinol. 2013;381:140-9 pubmed publisher
Lottrup G, Jørgensen A, Nielsen J, Jørgensen N, Duno M, Vinggaard A, et al. Identification of a novel androgen receptor mutation in a family with multiple components compatible with the testicular dysgenesis syndrome. J Clin Endocrinol Metab. 2013;98:2223-9 pubmed publisher
Hua S, Yao M, Vignarajan S, Witting P, Hejazi L, Gong Z, et al. Cytosolic phospholipase A2? sustains pAKT, pERK and AR levels in PTEN-null/mutated prostate cancer cells. Biochim Biophys Acta. 2013;1831:1146-57 pubmed publisher
Choucair K, Guérard K, Ejdelman J, Chevalier S, Yoshimoto M, Scarlata E, et al. The 16p13.3 (PDPK1) Genomic Gain in Prostate Cancer: A Potential Role in Disease Progression. Transl Oncol. 2012;5:453-60 pubmed
Park B, Park S, Koo J, Kim S, Park J, Cho J, et al. Homeodomain-interacting protein kinase 1 (HIPK1) expression in breast cancer tissues. Jpn J Clin Oncol. 2012;42:1138-45 pubmed publisher
McNamara K, Yoda T, Takagi K, Miki Y, Suzuki T, Sasano H. Androgen receptor in triple negative breast cancer. J Steroid Biochem Mol Biol. 2013;133:66-76 pubmed publisher
Chng K, Chang C, Tan S, Yang C, Hong S, Sng N, et al. A transcriptional repressor co-regulatory network governing androgen response in prostate cancers. EMBO J. 2012;31:2810-23 pubmed publisher
Baek K, Hong M, Jung Y, Lee C, Lee T, Park E, et al. Correlation of AR, EGFR, and HER2 Expression Levels in Prostate Cancer: Immunohistochemical Analysis and Chromogenic In Situ Hybridization. Cancer Res Treat. 2012;44:50-6 pubmed publisher
Park S, Park H, Koo J, Yang W, Kim S, Park B. Higher expression of androgen receptor is a significant predictor for better endocrine-responsiveness in estrogen receptor-positive breast cancers. Breast Cancer Res Treat. 2012;133:311-20 pubmed publisher
Ketola K, Hilvo M, Hyötyläinen T, Vuoristo A, Ruskeepää A, Oresic M, et al. Salinomycin inhibits prostate cancer growth and migration via induction of oxidative stress. Br J Cancer. 2012;106:99-106 pubmed publisher
Morin A, Fritsch L, Mathieu J, Gilbert C, Guarmit B, Firlej V, et al. Identification of CAD as an androgen receptor interactant and an early marker of prostate tumor recurrence. FASEB J. 2012;26:460-7 pubmed publisher
Vainio P, Wolf M, Edgren H, He T, Kohonen P, Mpindi J, et al. Integrative genomic, transcriptomic, and RNAi analysis indicates a potential oncogenic role for FAM110B in castration-resistant prostate cancer. Prostate. 2012;72:789-802 pubmed publisher
Park S, Koo J, Kim M, Park H, Lee J, Kim S, et al. Androgen receptor expression is significantly associated with better outcomes in estrogen receptor-positive breast cancers. Ann Oncol. 2011;22:1755-62 pubmed publisher
Vainio P, Gupta S, Ketola K, Mirtti T, Mpindi J, Kohonen P, et al. Arachidonic acid pathway members PLA2G7, HPGD, EPHX2, and CYP4F8 identified as putative novel therapeutic targets in prostate cancer. Am J Pathol. 2011;178:525-36 pubmed publisher
Yu Q, Niu Y, Liu N, Zhang J, Liu T, Zhang R, et al. Expression of androgen receptor in breast cancer and its significance as a prognostic factor. Ann Oncol. 2011;22:1288-94 pubmed publisher
Claassen H, Schicht M, Brandt J, Reuse K, Schädlich R, Goldring M, et al. C-28/I2 and T/C-28a2 chondrocytes as well as human primary articular chondrocytes express sex hormone and insulin receptors--Useful cells in study of cartilage metabolism. Ann Anat. 2011;193:23-9 pubmed publisher
Moss P, Lyles B, Stewart L. The PPAR? ligand ciglitazone regulates androgen receptor activation differently in androgen-dependent versus androgen-independent human prostate cancer cells. Exp Cell Res. 2010;316:3478-88 pubmed publisher
Koo J, Jung W, Jeong J. Metastatic breast cancer shows different immunohistochemical phenotype according to metastatic site. Tumori. 2010;96:424-32 pubmed
Gannon P, Godin Ethier J, Hassler M, Delvoye N, Aversa M, Poisson A, et al. Androgen-regulated expression of arginase 1, arginase 2 and interleukin-8 in human prostate cancer. PLoS ONE. 2010;5:e12107 pubmed publisher
Chen H, Libertini S, George M, Dandekar S, Tepper C, Al Bataina B, et al. Genome-wide analysis of androgen receptor binding and gene regulation in two CWR22-derived prostate cancer cell lines. Endocr Relat Cancer. 2010;17:857-73 pubmed publisher
Nodin B, Zendehrokh N, Brändstedt J, Nilsson E, Manjer J, Brennan D, et al. Increased androgen receptor expression in serous carcinoma of the ovary is associated with an improved survival. J Ovarian Res. 2010;3:14 pubmed publisher
Singh J, Xie C, Yao M, Hua S, Vignarajan S, Jardine G, et al. Food extracts consumed in Mediterranean countries and East Asia reduce protein concentrations of androgen receptor, phospho-protein kinase B, and phospho-cytosolic phospholipase A(2)alpha in human prostate cancer cells. J Nutr. 2010;140:786-91 pubmed publisher
Chen H, Libertini S, Wang Y, Kung H, Ghosh P, Mudryj M. ERK regulates calpain 2-induced androgen receptor proteolysis in CWR22 relapsed prostate tumor cell lines. J Biol Chem. 2010;285:2368-74 pubmed publisher
Waltering K, Helenius M, Sahu B, Manni V, Linja M, Janne O, et al. Increased expression of androgen receptor sensitizes prostate cancer cells to low levels of androgens. Cancer Res. 2009;69:8141-9 pubmed publisher
Iljin K, Ketola K, Vainio P, Halonen P, Kohonen P, Fey V, et al. High-throughput cell-based screening of 4910 known drugs and drug-like small molecules identifies disulfiram as an inhibitor of prostate cancer cell growth. Clin Cancer Res. 2009;15:6070-8 pubmed publisher
Yao M, Taylor R, Richards M, Sved P, Wong J, Eisinger D, et al. Prostate-regenerating capacity of cultured human adult prostate epithelial cells. Cells Tissues Organs. 2010;191:203-12 pubmed publisher
Vellaichamy A, Sreekumar A, Strahler J, Rajendiran T, Yu J, Varambally S, et al. Proteomic interrogation of androgen action in prostate cancer cells reveals roles of aminoacyl tRNA synthetases. PLoS ONE. 2009;4:e7075 pubmed publisher
Chen S, Kesler C, Paschal B, Balk S. Androgen receptor phosphorylation and activity are regulated by an association with protein phosphatase 1. J Biol Chem. 2009;284:25576-84 pubmed publisher
Péant B, Diallo J, Dufour F, Le Page C, Delvoye N, Saad F, et al. Over-expression of IkappaB-kinase-epsilon (IKKepsilon/IKKi) induces secretion of inflammatory cytokines in prostate cancer cell lines. Prostate. 2009;69:706-18 pubmed publisher
Bjorkman M, Iljin K, Halonen P, Sara H, Kaivanto E, Nees M, et al. Defining the molecular action of HDAC inhibitors and synergism with androgen deprivation in ERG-positive prostate cancer. Int J Cancer. 2008;123:2774-81 pubmed publisher
Urbanucci A, Waltering K, Suikki H, Helenius M, Visakorpi T. Androgen regulation of the androgen receptor coregulators. BMC Cancer. 2008;8:219 pubmed publisher
Wu Y, Li H, Lv X, Wei Q, Li X, Liu X, et al. Overexpression of JKTBP1 induces androgen-independent LNCaP cell proliferation through activation of epidermal growth factor-receptor (EGF-R). Cell Biochem Funct. 2008;26:467-77 pubmed publisher
Diallo J, Aldejmah A, Mouhim A, Fahmy M, Koumakpayi I, Sircar K, et al. Co-assessment of cytoplasmic and nuclear androgen receptor location in prostate specimens: potential implications for prostate cancer development and prognosis. BJU Int. 2008;101:1302-9 pubmed publisher
Ponti G, Losi L, Pellacani G, Rossi G, Presutti L, Mattioli F, et al. Wnt pathway, angiogenetic and hormonal markers in sporadic and familial adenomatous polyposis-associated juvenile nasopharyngeal angiofibromas (JNA). Appl Immunohistochem Mol Morphol. 2008;16:173-8 pubmed publisher
Ariazi E, Leitao A, Oprea T, Chen B, Louis T, Bertucci A, et al. Exemestane's 17-hydroxylated metabolite exerts biological effects as an androgen. Mol Cancer Ther. 2007;6:2817-27 pubmed
Compagno D, Merle C, Morin A, Gilbert C, Mathieu J, Bozec A, et al. SIRNA-directed in vivo silencing of androgen receptor inhibits the growth of castration-resistant prostate carcinomas. PLoS ONE. 2007;2:e1006 pubmed
Libertini S, Tepper C, Rodriguez V, Asmuth D, Kung H, Mudryj M. Evidence for calpain-mediated androgen receptor cleavage as a mechanism for androgen independence. Cancer Res. 2007;67:9001-5 pubmed
Araki S, Omori Y, Lyn D, Singh R, Meinbach D, Sandman Y, et al. Interleukin-8 is a molecular determinant of androgen independence and progression in prostate cancer. Cancer Res. 2007;67:6854-62 pubmed
Wang W, Bergh A, Damber J. Increased expression of CCAAT/enhancer-binding protein beta in proliferative inflammatory atrophy of the prostate: relation with the expression of COX-2, the androgen receptor, and presence of focal chronic inflammation. Prostate. 2007;67:1238-46 pubmed
Konduri S, Schwarz M, Cafasso D, Schwarz R. Androgen receptor blockade in experimental combination therapy of pancreatic cancer. J Surg Res. 2007;142:378-86 pubmed
Cordon Cardo C, Kotsianti A, Verbel D, Teverovskiy M, Capodieci P, Hamann S, et al. Improved prediction of prostate cancer recurrence through systems pathology. J Clin Invest. 2007;117:1876-83 pubmed
Tepper C, Vinall R, Wee C, Xue L, Shi X, Burich R, et al. GCP-mediated growth inhibition and apoptosis of prostate cancer cells via androgen receptor-dependent and -independent mechanisms. Prostate. 2007;67:521-35 pubmed
Ejskjaer K, Sørensen B, Poulsen S, Forman A, Nexø E, Mogensen O. Expression of the epidermal growth factor system in endometrioid endometrial cancer. Gynecol Oncol. 2007;104:158-67 pubmed
Havens A, Jung Y, Sun Y, Wang J, Shah R, Buhring H, et al. The role of sialomucin CD164 (MGC-24v or endolyn) in prostate cancer metastasis. BMC Cancer. 2006;6:195 pubmed
Tanyel F, Yüzbaşioğlu A, Kocaefe C, Orhan D, Ozguc M. Androgen receptor immunostaining and androgen receptor messenger ribonucleic acid expression are increased in cremaster muscles associated with undescended testis. Urology. 2006;67:855-8 pubmed
Theodoropoulos V, Tsigka A, Mihalopoulou A, Tsoukala V, Lazaris A, Patsouris E, et al. Evaluation of neuroendocrine staining and androgen receptor expression in incidental prostatic adenocarcinoma: prognostic implications. Urology. 2005;66:897-902 pubmed
Asioli S, Marucci G, Ficarra G, Stephens M, Foschini M, Ellis I, et al. Polymorphous adenocarcinoma of the breast. Report of three cases. Virchows Arch. 2006;448:29-34 pubmed
Ejskjaer K, Sørensen B, Poulsen S, Mogensen O, Forman A, Nexø E. Expression of the epidermal growth factor system in human endometrium during the menstrual cycle. Mol Hum Reprod. 2005;11:543-51 pubmed
Shah R, Mehra R, Chinnaiyan A, Shen R, Ghosh D, Zhou M, et al. Androgen-independent prostate cancer is a heterogeneous group of diseases: lessons from a rapid autopsy program. Cancer Res. 2004;64:9209-16 pubmed
Sonneveld E, Jansen H, Riteco J, Brouwer A, van der Burg B. Development of androgen- and estrogen-responsive bioassays, members of a panel of human cell line-based highly selective steroid-responsive bioassays. Toxicol Sci. 2005;83:136-48 pubmed
Das D, Shah R, Imperiale M. Detection and expression of human BK virus sequences in neoplastic prostate tissues. Oncogene. 2004;23:7031-46 pubmed
Nabi G, Seth A, Dinda A, Gupta N. Computer based receptogram approach: an objective way of assessing immunohistochemistry of androgen receptor staining and its correlation with hormonal response in metastatic carcinoma of prostate. J Clin Pathol. 2004;57:146-50 pubmed
Shi X, Ma A, Xia L, Kung H, de Vere White R. Functional analysis of 44 mutant androgen receptors from human prostate cancer. Cancer Res. 2002;62:1496-502 pubmed
product information
Product Type :
Antibody
Product Name :
Androgen Receptor Monoclonal Antibody (AR 441), Biotin
Catalog # :
MA5-13423
Quantity :
500µL
Price :
US 409
Clonality :
Monoclonal
Purity :
Protein G
Host :
Mouse
Reactivity :
Human
Applications :
Immunocytochemistry: 1:25-1:50, Immunofluorescence: 1:25-1:50, Immunohistochemistry (Paraffin): 1:25, Immunoprecipitation: 2 µg, Western Blot: 1:100-1:200
Species :
Human
Clone :
AR 441
Isotype :
IgG1
Storage :
4° C
Description :
The androgen receptor (AR) is a member of the steroid-hormone receptor superfamily of nuclear receptors. The receptor is more than 90 kDa and has three major functional domains: the N-terminal domain, DNA-binding domain, and the androgen-binding domain. The androgen receptor is a ligand-activated transcription factor that binds active testosterone (T) and dihydrotestosterone (DHT). Upon binding the hormone ligand, the receptor dissociates from accessory proteins, translocates into the nucleus, dimerizes, and then stimulates transcription of androgen responsive genes. The AR signaling pathway plays a key role in development and function of male reproductive organs, including the prostate and epididymis. AR also plays a role in nonreproductive organs, such as muscle, hair follicles, and brain. Androgen Receptor is a phosphoprotein, and also regulates mitogen-activated protein kinase (MAP kinase). The inhibition of the MEK1/2 pathway correlates directly with a change in phosphorylation state of the androgen receptor. Abnormalities in the AR signaling pathway have been linked to a number of diseases, including prostate cancer, Kennedy's disease, and male infertility.  Mutations in this gene are associated with complete androgen insensitivity (CAIS).
Immunogen :
Synthetic peptide corresponding to Human Androgen Receptor aa 299-315
Format :
Liquid
Applications w/Dilutions :
Immunocytochemistry: 1:25-1:50, Immunofluorescence: 1:25-1:50, Immunohistochemistry (Paraffin): 1:25, Immunoprecipitation: 2 µg, Western Blot: 1:100-1:200
Aliases :
AIS; Andr; androgen nuclear receptor variant 2; Androgen receptor; androgen receptor (dihydrotestosterone receptor; testicular feminization; spinal and bulbar muscular atrophy; Kennedy disease); androgen receptor (Testicular feminization), same as Tfm; androgen receptor AR; androgen receptor splice variant 4b; AR; AR8; AR-A; AW320017; DHTR; Dihydrotestosterone receptor; HUMARA; HYSP1; KD; NR3C4; Nuclear receptor subfamily 3 group C member 4; RP11-383C12.1; SBMA; SMAX1; Tfm; Variant AR45
company information
Invitrogen
Thermo Fisher Scientific
81 Wyman Street
Waltham, MA USA 02451
https://www.thermofisher.com
800-678-5599
headquarters: USA